Oncotarget · 2017 · 38 citations · 32 references
Life SciencesGeneticsMolecular BiologyEpigeneticsGene ExpressionMolecular OncologyDna Methylation ProfilingEpigenetic Alterations In CancerEpigenetic BiomarkersEpigenetic Regulation In CancerMicrorna BiologyNoncoding Rna In CancerAcute Myeloid Leukemia BiologyDna Methylation PatternsMicrorna-mediated Epigenetic ControlPromoter HypermethylationPromoter MethylationPromoter Methylation AnalysisQuantitative Pcr DetectionReal-time Polymerase Chain Reaction (Pcr)
// Hongxia Yao 1, * , Mengling Duan 1, * , Lie Lin 1 , Congming Wu 1 , Xiangjun Fu 1 , Hua Wang 1 , Li Guo 1 , Wenting Chen 1 , Li Huang 1 , Dan Liu 1 , Ruo Rao 1 , Shuwen Wang 1 , Yipeng Ding 2 1 Department of Hematology, Hainan General Hospital, Haikou, Hainan, 570311, P.R. China 2 Department of Emergency, Hainan General Hospital, Haikou, Hainan, 570311, P.R. China * These authors have contributed equally to this work Correspondence to: Hongxia Yao, email: yaohongxiahk@163.com Keywords: AML, Hainan, LncRNA MEG3, TET2, rtPCR Received: December 02, 2016 Accepted: January 11, 2017 Published: February 17, 2017 ABSTRACT The promoter of MEG3 , which encodes the long non-coding RNA (lncRNA) MEG3, is often hypermethylated in acute myeloid leukemia (AML). Additionally, the Tet methylcytosine dioxygenase 2 gene ( TET2 ) is frequently inactivated, which can lead to impaired DNA methylation and promote AML development. We examined the association between TET2 and MEG3 promoter hypermethylation in Hainan patients with AML. The expression of MEG3, TET2, miR-22-3p, and miR-22-5p was assessed in bone marrow samples from AML patients and healthy controls using real-time quantitative PCR. Using Sequenom MassARRAY technology, we compared MEG3 promoter methylation in AML patients and healthy controls. MEG3 expression was lower in AML patients than in the controls (P = 0.136). Moreover, there was greater methylation of MEG3 promoter in the AML patients than the controls (P < 0.05). Methylation of the MEG3 promoter correlated negatively with TET2 expression (P < 0.05, r < 0). Likewise there was a negative correlation between TET2 activity and MEG3 promoter methylation (P < 0.05, r < 0). These results suggest that hypermethylation of the MEG3 promoter in AML may result from decreased TET2 activity. These data provide insight into the molecular mechanisms underlying AML development and progression.
32
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Mamta Tahiliani, Kian Peng Koh, Yinghua Shen et al. · Science · 2009 · 5.8K citations · Full text
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis
Rajnish A. Gupta, Nilay Shah, Jeewon Kim et al. · Nature · 2010 · 5.3K citations · Full text
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals
Mitchell Guttman, Ido Amit, Manuel Garber et al. · Nature · 2009 · 4.2K citations · Full text
Mutation in <i>TET2</i> in Myeloid Cancers
François Delhommeau, Sabrina Dupont, Véronique Della Valle et al. · New England Journal of Medicine · 2009 · 1.7K citations · Full text